November 21st 2024
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Type 2 Diabetes, Metformin, and Cardioprotection: Are the Data There?
May 14th 2013Metformin and the class of sulfonylureas are the "work horses" of therapy for type 2 diabetes. Metformin even confers some protection from vascular complications. But, how do they stack up against newer agents? Here, a closer look.
Managing Diabetes in Older Patients: Consensus Report
October 31st 2012What is known about diabetes mellitus in older adults, how DM affects them differently than younger adults, what can be done to prevent or manage the disease, and how best to fill critical gaps in the evidence to address older patients’ needs.